Arshad Aysha, Mandava Anisha, Kamath Ganesh, Musat Dan
Division of Cardiology, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA.
Prog Cardiovasc Dis. 2008 May-Jun;50(6):420-38. doi: 10.1016/j.pcad.2007.12.003.
Sudden cardiac death (SCD) accounts for more than 300,000 deaths annually in the United States. The goal of medical therapy in patients considered to be at high risk (coronary artery disease, post myocardial infarction, structural heart disease and congestive heart failure) involves treating the disease state as well prevention of potentially lethal arrhythmias. Treatment with angiotensin receptor inhibitors, beta blockers and statins has been shown to improve survival in this high risk group. The use of anti-arrhythmic drugs has been studied and found to lack efficacy and has potential for adverse effects. The role of omega-3 fatty acids in preventing sudden death continues to evolve.
在美国，心脏性猝死（SCD）每年导致超过30万人死亡。对于被认为是高危人群（冠状动脉疾病、心肌梗死后、结构性心脏病和充血性心力衰竭）的患者，药物治疗的目标包括治疗疾病状态以及预防潜在的致命性心律失常。已证明使用血管紧张素受体抑制剂、β受体阻滞剂和他汀类药物可提高该高危人群的生存率。抗心律失常药物的使用已得到研究，发现其缺乏疗效且有潜在不良反应。ω-3脂肪酸在预防猝死方面的作用仍在不断演变。
